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Background: To identify novel small molecules against the TSH receptor, we developed 
a sensitive transcription-based luciferase high-throughput screening (HTS) system 
named the TSHR-Glo Assay (TSHR-Glo).
Methods: This assay uses double-transfected Chinese hamster ovary cells stably 
expressing the human TSHR and a cAMP-response element (CRE) construct fused to 
an improved luciferase reporter gene.
Results: The assay was highly responsive toward TSH in a dose-dependent manner 
with a TSH sensitivity of 10−10M (10 ± 1.12 μU/ml) and thyroid-stimulating antibodies, a 
hallmark of Graves’ disease, could also be detected. The assay was validated against 
the standard indicator of HTS performance – the Z-factor (Z′) – producing a score of 
0.895. Using the TSHR-Glo assay, we screened 48,224 compounds from a diverse 
chemical library in duplicate plates at a fixed dose of 17 μM. Twenty molecules with 
the greatest activity out of 62 molecules that were identified by this technique were 
subsequently screened against the parent luciferase stable cell line in order to eliminate 
false positive stimulators.
Conclusion: Using this approach, we were able to identify specific agonists against the 
TSH receptor leading to the characterization of several TSH agonist molecules. Hence, 
the TSHR-Glo assay was a one-step cell-based HTS assay, which was successful in 
the discovery of novel small molecular agonists and for the detection of stimulating 
antibodies to the TSH receptor.
Keywords: tsh receptor, small molecule, screening, high-throughput, thyroid-stimulating hormone
INtRodUCtIoN
The thyrotropin-stimulating hormone receptor (TSHR), expressed on the cell surface of thyrocytes, 
initiates the major trophic signals that direct thyroid cell growth and hormone synthesis/secretion 
(1, 2). The TSHR is also a target autoantigen in autoimmune thyroid disease, especially Graves’ 
disease (3–5). In addition to its expression on the thyroid cell, it is now well established that the TSHR 
Abbreviations: CHO, Chinese hamster ovary cells; HTS, high-throughput screening; SML, small-molecule ligands; TSH, 
thyroid-stimulating hormone; TSHR, TSH receptor; TSHR-Glo, TSH receptor glow.
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is expressed in a variety of extra-thyroidal tissues, including bone 
cells, fibroblasts, and adipocytes, where it is known to modulate 
target cell function (6–11). In the thyroid, TSHR activation and 
coupling of G proteins leads to a cascade of complex intracellular 
events, resulting in thyrocyte growth and hormone production. 
Activation of Gαs stimulates the production of adenyl cyclase, 
which leads to an increase in cyclic adenosine monophosphate 
(cAMP) generation, whereas simultaneous Gq stimulation leads 
to PI3 kinase activation. The increases in cAMP and PI3 kinase 
via protein kinase A (PKA) and phospholipase C (PLC) cause the 
thyrocyte growth, differentiation, and thyroid hormone synthe-
sis. In addition to engaging Gαs and Gαq, the TSHR is capable of 
activating the MAP kinase pathway via Gβγ and RhoGEF through 
G12/13. It is not yet clear as to which isoform of the G proteins is 
effectively used in the different tissues modulating the function of 
the TSHR. However, the use of either small molecules that bind 
to an orthosteric/allosteric site on the receptor or monoclonal 
antibodies to the receptor ectodomain have great therapeutic 
potential in the treatment of patients with thyroid dysfunction, 
especially hyperthyroid Graves’ disease, extra-thyroidal manifes-
tations of Graves’ disease in the eyes and skin, and also in the 
investigation and treatment of differentiated thyroid cancer (12).
Recently, small molecular agonists and antagonists to the 
TSHR have become attractive therapeutic options because of their 
low cost of synthesis and ability to efficiently cross the plasma 
membrane of cells compared to recombinant TSH. These novel 
small molecules can be identified either by high-throughput 
screening (HTS) of large chemical libraries or by virtual docking 
and chemoinformatic approaches or a combination of both. The 
first small-molecule agonist against the TSHR was described 
nearly 8  years ago (13) and has been subjected to chemical 
modifications to improve its specificity and potency (14), and we 
have described two more recent molecules with similar potency 
but different structures (15). Such small-molecule agonists to the 
TSHR have the potential to be used as an effective substitute to 
recombinant TSH, which is difficult and expensive to produce 
(16) and, furthermore, small molecules may be more effective 
probes in the detection of thyroid cancer. In contrast, potent 
antagonists against the TSHR would be useful for the treatment 
of hyperthyroid Graves’ disease by blocking thyroid-stimulating 
antibodies without the risk of anti-thyroid drug side effects (17) 
and may also have a role in treating Graves’ eye disease (18). To 
date, it is not clear if the reported small-molecule ligands have 
enough potency to enter clinical trials. Hence, there remains a 
strong need for identifying and developing additional novel 
small molecules of higher potency, better stability, and improved 
pharmacodynamics and pharmacokinetics (19).
High-throughput screening methods are required to incor-
porate speed, efficiency, robust signal detection, and low reagent 
consumption in addition to sensitivity, reproducibility, and 
accuracy of detection. A standard HTS assay needs to be in a 
format that is easily adaptable for automated liquid handling and 
signal detection systems. Thus, to identify novel small-molecule 
agonists to the TSHR, we developed an in-house HTS assay called 
the TSH Receptor Glo assay (TSHR-Glo). This is a simple, one-
step and cell-based functional cAMP assay, which has proven 
amenable for automation and liquid handling in a 348-well 
format for HTS of compound libraries. It is sensitive, reproduc-
ible, and cost-effective. Although this method was already used 
to screen small-molecule agonists to the TSH receptor (15), this 
paper describes in detail the full evaluation of optimization and 
validation of this assay.
MAteRIALs ANd Methods
Materials
Bovine TSH (Cat # T8931) and forskolin (Cat # F6886) were 
purchased from Sigma-Aldrich (St. Louis, MO, USA). The 
lysis and luciferase substrate (Bright-Glo) reagent utilizing a 
one-step preparative procedure was purchased from Promega 
Corporation, WI (Cat # E2610). Selected small molecules were 
purchased through ChemBridge Corporation, San Diego, CA, 
USA. Cell culture medium including Ham’s F12 (Cat # 10-080-
CV) was purchased from Cellgro, Manassas, VA, USA and fetal 
bovine serum (FBS) (Cat # S11195) and calf serum (S11495) were 
purchased from Atlanta Biologicals, Flowery Branch, GA, USA.
Generation of stable Cells for Bioassay
We generated stable double transfectants by using a pGL4.29 
[luc2P/CRE/Hygro] construct, having a minimal promoter 
driving a CREB response element tagged to a modified form of 
luciferase reporter gene luc2P (Promega Corporation, Madison, 
WI, USA), into our stable line of Chinese hamster ovary (CHO) 
cells expressing the human TSH receptor with a N-terminus 
hemagglutinin (HA) tag (CHO-HA:TSHR cells) (20). Several 
stable clones harboring both the TSH receptor and luciferase con-
struct were selected by using high concentrations of hygromycin 
(800 μg/ml). To test for false positive hits in our screen, we also 
generated a stable line of parent CHO cells with the luciferase 
construct lacking the TSH receptor by transfecting the pGL4.29 
(luc2P/CRE/Hygro) construct into the CHO cells and selecting 
with hygromycin. The functionality and specificity of these parent 
stable clones were selected based on different concentrations of 
forskolin and their total unresponsiveness to TSH. These stable 
cell lines were maintained in Ham’s F-12 medium with 10% of 
FBS, 100  IU/ml of penicillin, 100  μg/ml of streptomycin, and 
50 μg/ml of hygromycin.
tshR-Glo Assay
The screening assay employed a selected high expressing stable 
line of CHO-HA-TSHR luciferase cells as described above. 
Activation of the TSH receptor by TSH or an agonist in these cells 
results in the release of Gsα from the trimeric G-protein complex 
for adenylate cyclase coupling increases intracellular cAMP, 
which then binds to the CRE promoter resulting in the transcrip-
tion of luciferase gene and accumulation of luciferase enzyme 
within the activated cells. Luciferase in these cells was detected 
after lysing the cells using the commercial substrate Bright-Glo. 
Although the assay was initially developed on a standard 96-well 
plate, it was subsequently miniaturized to function in a 384-well 
format in a total assay volume of 16  μl to minimize reagent 
consumption and assay costs. Compounds were added from a 
384-well stock plate using pin tool, thus transferring 17 nl from 
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FIGURe 1 | tsh dose–response and hts optimization. (A) The TSHR-Glo cells were tested against bovine TSH and a WHO international standard human TSH 
(81/565 obtained from NIBSC). Inset: shows the response curve using recombinant human TSH. (B) To optimize the use of the assay as an HTS method, we 
performed a similar TSH dose–response using different cell densities on a proxy-shallow 384-well plate and calculated the Z factor scores under each cell density. 
A Z factor score of 0.895 with 15,000 cells/well was adopted as the standard format of cell density for HTS screening [note: 1 ≥ z ≥ 0.5 is considered an 
excellent assay (23)]. Luciferase is measured on a luminescence based microplate reader after lysis of the cells with a one-step reagent and expressed as luciferase 
units (LU).
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10 mM stock into 10 μl of culture medium containing the cells. 
This single-step assay was easily adaptable to liquid handling and 
automation.
For HTS, we seeded 15,000 cells of HA-TSHR luci cells per 
well in a 384-opaque white bottom poxi-plate (PerkinElmer-
ProxiPlate, Cat # 6008230) using Multidrop Combi dispenser 
(Thermo Fisher) in 10 μl of Ham’s F12 complete medium and 
incubated overnight at 37°C in a 5% CO2 incubator with relative 
humidity of >85%. Small-molecule libraries were transferred 
from 384-well stock plates containing 10  mM solutions in 
DMSO (Chembridge Corporation, San Diego, CA, USA). Small-
molecule addition was accomplished using a 384-tip pin tool 
(V&P Scientific, San Diego, CA, USA) transferring 17 nl per pin 
(based on fluorimetric calibration), resulting in a final concen-
tration of 17  μM per well. Plate validation and normalization 
controls, including negative control (medium only) with 0.1% 
DMSO and a positive agonist molecule previously described (14), 
were added to blank wells located in the first two and last two 
columns of each plate. Following compound addition, plates were 
incubated for 4 h at 37°C. At the end of 4 h, the cells were lysed by 
adding 6 μl of Bright-Glo reagent and incubated for 2 min before 
measuring luciferase activity using an EnVision Multilabel Plate 
Reader (PerkinElmer, Branford, CT, USA).
hts screening
The L1 library, a collection of 100,000 structurally diverse mol-
ecules from Chembridge Corp., San Diego, CA, USA, selected 
based on their drug-like properties as defined by Lipinski’s “Rule 
of Five” (21), was obtained from the Integrated Screening Core at 
Icahn School of Medicine at Mount Sinai, NY, USA. The actual 
screen of the compound library was performed at a final concen-
tration of 0.1% DMSO so that the final concentration of DMSO 
did not interfere in the assay.
Intra- and Inter-Assay CV
To determine the inter assay variation of the TSHR-Glo bioassay, 
we tested our positive control at 17 μM in five different plates 
in triplicates and calculated the mean and SD and for the intra-
assay variation, we took five calculations of the positive control 
at 17 μM in the same plate in duplicates and calculated the mean 
and SD for each of these readings and % coefficient of variability 
(CV) for them followed with an average% CV. The results of this 
are shown as tables.
The heteroscedasticity of this assay was also examined by tak-
ing different dilutions (0–105 μU/ml) of bovine TSH in 15,000 
cells plated in 384-well plate and performed the assay five times in 
same plate and similar dose–response done in five different plates 
at different time points. The results of this were plotted as graph 
and % CV for this is indicated.
serum samples
Serum samples used in this study were unidentifiable stored 
samples originally collected with the full consent of the patients.
data Analyses
All curve fittings were performed using GraphPad Prism version 
5.02.
ResULts
Assay optimization
To develop the reporter system, a stable clone of double-
transfected HA-TSHR and CRE luciferase (HATSHR-Luci#1) 
cells was selected from several double-transfected clones 
using high concentrations of neomycin sulfate (G418) and 
Zeocin. We examined this clone for sensitivity to TSH in a 
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FIGURe 3 | specificity of the tshR-Glo assay. (A) The specificity of the assay was examined by dose–responses curves against TSH, hCG, and FSH 
hormones. As indicated, the assay showed no responses to hCG or FSH at the concentrations tested here but a dose-dependent increase in luciferase signal. (B,C) 
In order to test the heteroscedasticity of the assay, we measured response of increasing doses of TSH in an inter- and intra-assay format as indicated by graphs. 
Intra-assay exhibited very minimal variability compared to the inter assay though both had CVs <5%.
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FIGURe 2 | effect of time and dMso on tshR-Glo assay. (A) Since this is a transcriptional based assay, we wanted to evaluate the effect of time. For this, the 
assay was performed with 10−9M (100 μU/ml) of TSH and time periods of 1, 2, 3, and 4 h without (0TSH) and with TSH treatment. Though a measurable difference 
in response to TSH was observed in 2 h, the response at 4 h was taken as the optimum time of incubation required for the screening because of the robust signal. 
(B) Since the library compounds were held in DMSO, it was imperative to test the effect of DMSO on the TSHR-Glo assay. The bars show the effect of increasing 
concentrations of DMSO on stimulation of the cells with TSH. We found that the bioassay could tolerate DMSO concentrations up to 1%. However, the 
concentration of DMSO in our actual screen was 0.1% DMSO.
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tABLe 1 | Inter-assay coefficient of variability of the tshR-Glo assay.
Inter-assay CV
Control Result (LU) Plate Mean
1 352,506 1
2 280,657
3 318,836 317,333
1 270,003 2
2 284,091
3 313,812 289,302
1 389,570 3
2 390,237
3 405,448 395,085
1 404,723 4
2 426,760
3 411,320 414,267
1 380,766 5
2 381,992
3 417,211 393,323
Mean of mean 361,862.13
SD of mean 54,972.04
% CV of means 15.19
tABLe 2 | Intra-assay coefficient of variability of the tshR-Glo assay.
Intra-assay CV
Control Result Result2 Mean sd % CV
1 352,506 354,343 353,424.5 1298.955157 0.367533987
2 280,657 291,041 285,849 7342.596816 2.568697745
3 318,836 304,639 311,737.5 10,038.79497 3.220271855
4 284,091 330,204 307,147.5 32,606.815 10.61601185
5 313,812 291,778 302,795 15,580.39082 5.145524469
Average% CV 4.38
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dose–response stimulation assay with commercial bovine TSH 
and the WHO International human TSH standard (81/565 
obtained from NIBSC), which is the same pituitary extract as 
the second IRP for TSH 80/558 stock. Both TSH preparations 
showed good correspondence with each other in the TSHR-Glo 
assay (Figure 1A). We then used this heterologous cell (CHO) 
overexpressing the TSH receptor in our HTS. The bioassay 
was sensitive enough to respond to 10 ±  1.12 μU/ml of TSH 
(10−10M).
In agreement with the bovine TSH and International human 
TSH Standard, a similar dose–response to recombinant human 
TSH was observed (Figure 1A inset) indicating that the activa-
tion of CRE luciferase was not due to any other contaminating 
proteins. CHO cells transfected with only the luciferase construct 
showed no responses to bovine TSH as indicated by the inverted 
triangle in Figure 1A. In order to scale down the assay to HTS 
format, we examined the effect of different cell densities ranging 
from 5000 cells per well to 20,000 cells per well in shallow proxy 
plates cultured in 10 μl of medium overnight with >85% relative 
humidity. We selected 15,000 cells per well for all subsequent 
measurements since this displayed the highest signal-to-baseline 
ratio after the 4-h incubation time with TSH giving a Z factor 
score of 0.895 between 0 and 10−8M (1000  μU/ml) of TSH 
(Figure 1B).
Time-course experiments from 30  min to 4  h using 10−9M 
(100  μU/ml) of TSH indicated that a signal-to-basal ratio of 
>2-fold was only achieved when the incubation time reached 
4 h or greater suggesting that the assay, although sensitive, was 
not a rapid technique (Figure  2A). An incubation time of 4  h 
after the addition of the compounds was chosen as the endpoint 
for the assay based on the difference between the signal and the 
background observed. Since the majority of library compounds 
are solubilized in dimethyl sulfoxide (DMSO), we also examined 
the effect of DMSO on TSH responsiveness. By this titration of 
DMSO, we observed a tolerance of 0.625% of DMSO, which had 
no detectable effect on the TSH-stimulated signal in the TSHR-
Glo assay (Figure 2B).
The specificity of the assay was assessed by stimulating the 
reporter cell line with FSH and hCG ligands for homologous 
(GPCR) receptors, which are not expressed in this CHO cell 
line. As expected, neither of these hormones had any effect while 
increasing concentrations of bovine TSH elicited the expected 
response (Figure 3A).
In order to express the precision and reproducibility of the 
TSHR-Glo assay, we measured the inter- and intra-assay CV and 
gaged the heteroscedasticity in the assay (Figures 3B,C). These 
studies indicated a tight fit for the intra- and inter-assay vari-
ability with low CV when using a reported agonist as a positive 
control (14) (Tables 1 and 2). The mean inter-assay CV was 15%, 
whereas the intra-assay % CV was 4.38. These values indicated 
the suitability of the TSHR-Glo assay for further use as an HTS 
assay for identification of small-molecule agonists to the TSHR.
tsh Receptor Antibody Responses
We initially observed that a monoclonal thyroid-stimulating 
antibody induced potent responses in the system, while a TSH 
receptor-blocking monoclonal antibody (22) was incapable of 
signaling (Figure  4). To determine if the TSHR-Glo assay was 
useful in measuring stimulating antibodies in patients with 
Graves’ disease, we used sera with known TSHR antibodies and 
control sera that were negative (Figure  5). The data indicated 
that the TSHR-Glo assay provides a sensitive (limits of detection: 
10–100 mIU/l) and a selective assay for also measuring agonist-
like responses in Graves’ disease patient’s sera.
high-throughput screening of a Chemical 
Library
Screening a total of 137 plates with 384 wells each using the TSHR-
Glo assay, we obtained a Z-factor in the range of 0.7–0.8 based 
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FIGURe 4 | Response of tshR-Glo against stimulating and blocking 
monoclonal antibody – further proof of the specificity of the assay 
was obtained by testing a stimulatory monoclonal antibody (Ms-1) 
and blocking (non-stimulatory) monoclonal tshR antibody (K1-70) in 
the assay. MS-1 stimulated luciferase activity in a dose-dependent manner, 
whereas K1-70 was unable to show any response in the assay even at the 
highest concentration.
esareficuL
01
x
stinu
4
Graves’ disease sera Normal sera Rheumatoid 
arthritis sera
Back
ground
Control
antibodies
LogTSH (M)
0
10
20
30
40
50
60
70
80
90
100
FIGURe 5 | Agonist activity measured in patient sera using tshR-Glo. Graves’ disease patient and normal sera were diluted 1:5 in medium. Ten of the 12 GD 
(Graves’ disease) serum samples (denoted GD with dark gray bars) stimulated the production of cAMP in contrast to no stimulation observed with any of the normal 
(denoted NS with light gray bars) or rheumatoid arthritis (denoted RA with black bars) patient sera. Background is denoted by the two filled hatched bars, a 
human-stimulating monoclonal antibody (M22 shown as hatched bar), human-blocking monoclonal antibody (K1-70 shown as filled criss-cross bar) 1 μg/ml, and 
bovine TSH (gray bars) at increasing log concentrations.
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against a positive control used on each plate (Figure 6A). These Z 
values exceeded the commonly accepted threshold (0.5) for vali-
dation of high-throughput assays (23). The signal-to-background 
ratio was linear and the mean CV was within an acceptable value 
5–20% for a bioassay (Figures 6B,C). Using this HTS assay, we 
examined 48,224 molecules for agonist activity before suspend-
ing the screen because of the large number of positive results 
(hits) based on our selection criteria. All of the compounds were 
screened at a single concentration of 17 μM in duplicate plates. We 
then selected positive samples only if a “significant” response was 
obtained in both plates, with significance defined as a response 
greater than mean ± 3 SD compared to the negative control. This 
screening resulted in 63 responder molecules yielding a hit value 
of 0.13%. We subjected 21 of the molecules that generated the 
strongest signal to a second confirmatory testing using CHO 
luciferase cells (parent CHO cells without the TSH receptor but 
stably transfected with luciferase construct). Based on this second 
round of testing for false activation, we eliminated two molecules 
that stimulated the non-TSHR containing CHO cells. We then 
selected two compounds, named MS437 and MS438 (marked 
with an asterisk), as our lead molecules, which showed >10-fold 
responses above the baseline and no activity on the parent CHO 
luciferase cells. These lead molecules were further characterized 
for their specificity, binding, and their in vivo activity as described 
elsewhere (15).
dIsCUssIoN
The thyroid-stimulating hormone receptor is not only a major 
regulator of thyroid function but also plays a major role in several 
thyroid pathologies, including hyperthyroidism, hypothyroid-
ism, and thyroid tumors (5). Further, its ubiquitous presence in 
other tissues of the body, such as adipocytes, fibroblasts, bone 
cells, and immune cells, has expanded its role in these tissue 
depots (24), although the physiological relevance of the recep-
tor in these extra-thyroidal sites is still being revealed. Though 
various effective treatment strategies are currently available 
for the treatment of thyroid conditions, not all of these are 
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FIGURe 6 | evaluation of hts performance. (A) Z factor was calculated 
by taking the positive control and basal control responses of each duplicate 
plate and using the formula Z′ = 1 − (3 × SD of total signal + 3 × SD of basal 
signal)/(total signal − basal signal) as indicated by Zhang et al. (23).  
(B) Signal-to-background ratio (S/B): total signal was obtained from 
alternating wells of columns 1 and column 22 using 17 μM of positive control 
and background signal was were collected from the alternating wells of 
column 1 and column 22 treated with medium containing 0.1% DMSO.  
(C) Coefficient of variation (% CV), calculated as the SD from the wells in the 
basal medium divided by the wells of the positive control in all 137 plates.
January 2016 | Volume 7 | Article 37
Latif et al. HTS and TSH Receptor
measure Gs activation in GPCRs. One such CNG-coupled cAMP 
assay employing a membrane potential dye has been previously 
described as a high-throughput assay for screening agonists 
against the TSHR (27). Auto-fluorescing compounds constitute 
a large bulk of compound libraries, thus discouraging us from 
using such a fluorescence-based readout for bulk screening and 
providing an advantage to a transcriptional-based luciferase 
cAMP assay described here. The TSHR-Glo assay was based on a 
stable overexpressed system; it is robust in producing signal and 
easily meets the criteria for an HTS assay by having high Z scores. 
In addition, over-expressed systems are well known to produce 
a better signal-to-noise ratio than native lines. Furthermore, 
CHO cells, in particular, are easy to culture and robust enough 
to be handled by automation. The TSHR-Glo assay described is 
based on double-transfected CHO cells harboring the full-length 
receptor and CRE response element tagged to an improved 
synthetically derived luciferase reporter gene (luc2P). Luc2P is 
a modified firefly luciferase sequence with humanized codon 
optimization that is designed for high expression and reduced 
anomalous transcription. In addition, the luc2P gene contains 
hPEST, a protein destabilization sequence, which further 
reduces background transcribed protein (28). All these factors 
had a cumulative effect in developing this assay for HTS of a 50k 
chemical library. The positive hits were initially confirmed for 
specificity using the parent cells without the receptor but having 
the CRE luciferase vector stably transfected into them. These cells 
responded well to forskolin, an adenylyl cyclase activator but not 
to TSH. Further confirmation of the specific hits was obtained 
with other orthogonal assays, such as real-time PCR in native 
cells and with in vivo testing (15).
Although the TSHR-Glo assay is a sensitive and robust HTS 
assay, it is not a rapid technique because the time between the 
addition of stimulant and final read is 4 h. We think that the time 
lag in the assay is due to the time-dependent accumulation and 
folding of luciferase within the cells needed to reach a detect-
able threshold unlike other enzyme-linked assays that directly 
measure second messengers, such as cAMP. As an HTS assay, 
the TSHR-Glo assay also showed a good tolerance to DMSO 
concentrations within the working limits of any library screening. 
Further, on checking the specificity of this assay against FSH and 
hCG responses, we found almost no response. The assay also had 
good intra- and inter-assay% CV as indicated in Figure  4 and 
Tables 1 and 2.
To identify hits from large chemical libraries, an assay has to 
be sensitive and precise, and thus, a successful screen depends 
critically on the quality of the HTS assay used. Although the cri-
teria or parameters for evaluating the suitability of an HTS assay 
for hit identification are not well defined, a screening window 
coefficient, called the Z-factor is accepted as the “gold standard” 
(23). Z-factor is a dimensionless, simple statistical coefficient, 
which is reflective of both the assay signal dynamic range and 
the data variation associated with the signal measurements, and 
therefore, it is suitable for assay quality assessment. The Z-factor 
has proven to be a useful tool in HTS assay optimization and vali-
dation (23). TSHR-Glo assay proved to have an excellent Z score 
of 0.895 to fit this criteria and which was well above the Z factor 
score of >0.5 considered as a satisfactory standard for a HTS 
devoid of side effects (25). Thus, there has been great impetus 
to develop newer therapeutics for the treatment of thyroid 
disease, especially Graves’ disease. One such therapeutic area of 
development has been identifying small molecules, which can 
bind to the receptor and modify their signaling in a positive or 
negative allosteric effect (19). In this manuscript, we describe 
in detail the development and use of a high-throughput assay 
for identifying novel small-molecule agonists against the TSH 
receptor.
Since the TSH receptor is known to couple to various G 
proteins (26), bioassays have been largely designed to measure 
their activation. Fluorescence polarization, homogenous 
time-resolved fluorescence (HTRF) or enzyme fragmentation 
complementation, and cyclic nucleotide-gated ion channel 
(CNG) – coupled are some of the commonly used approaches to 
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(2) an assay for thyroid-stimulating antibodies of Graves’ disease, 
and (3) for the selection of monoclonal antibodies against the 
TSH receptor.
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